Expression of p21Waf1/Cip1 predicts response and survival of esophageal cancer patients treated by chemoradiotherapy

Diseases of the Esophagus

Volumn 17, Issue 4, 2004, Pages 315-321

  Nakamura, Tsutomu ^a   Hayashi, K ^a   Ota, M ^a   Ide, H ^a   Takasaki, K ^a   Mitsuhashi, M ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

CDC25B; Chemoradiotherapy; Cyclin D1; p21; p53; Squamous cell carcinoma

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLUOROURACIL; NEDAPLATIN; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE;

ADVANCED CANCER; ARTICLE; BEAM THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION FUNCTION; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

BIOPSY; CARCINOMA, SQUAMOUS CELL; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; CHEMOTHERAPY, ADJUVANT; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12344265532     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2004.00433.x     Document Type: Article

References (30)

1. Ilson D H, Kelsen D P. Combined modality therapy in the treatment of esophageal cancer. Semin Oncol 1994; 21: 493-507.
2. Geh J I. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002; 38: 300-13.
3. Vogel S B, Mendenhall W, Sombeck M D, Marsh R, Woodward E R. Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995; 221: 685-95.
4. Geh J I, Crellin A M, Glynne-Jones R. Preoperative (neo-adjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88: 338-56.
5. Bosset J F, Gignoux M, Triboulet J P et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-7.
6. Urba S G, Orringer M B, Trrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-13.
7. Lowe S W, Ruley H E, Jacks T, Housman D E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
8. Ribeiro U Jr, Finkelstein S D, Safatle-Ribeiro A V et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83: 7-18.
9. Ito T, Kaneko K, Makino R et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 2001; 36: 303-11.
10. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert H E. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998; 4: 2991-7.
11. Krasna M J, Mao Y S, Sonett J R et al. P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg 1999; 68: 2021-5.
12. Waldman T, Kinzler K W, Vogelstein B. p21 is necessary for p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5189-90.
13. Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, García-Aguilar J. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000; 43: 451-9.
14. WAF1 expression is associated with improved survival after adjuvant chemoradiotherapy for pacreatic cancer. Surgery 2000; 128: 520-30.
15. Samejima R, Kitajima Y, Yunotani S, Miyazaki K. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 1999; 19: 5515-22.
16. Miyata H, Doki Y, Shiozaki H et al. CDC25B and p53 are independently implicated in human esophageal cancers. Clin Cancer Res 2000; 6: 4859-65.
17. International Union Against Cancer (UICC), Sobin L H, Wittekid C, eds. TNM Classification Of Malignant Tumors, 5th edn. New York: John Wiley & Sons, 1997.
18. Uchida N, Takada Y, Hojo K, Maekawa R, Sugita K, Yoshioka T. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer 1998; 34: 1796-801.
19. Japanese Society for Esophageal Diseases. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th edn. Tokyo: Kanehara, & Co Ltd, 2001.
20. Bartelink H, Schellens J H M, Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumors. Eur J Cancer 2002; 38: 216-22.
21. WAF1, bcl-2, and bax) and sensitivity to chemotherapy in squamous cell carcinoma of the esophagus. Int J Clin Oncol 2000; 5: 89-96.
22. Caffo O, Doglioni C, Veronese S et al. Prognostic value of p21WAF1 and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591-9.
23. Waldman T, Zhang Y, Dillehay L et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med 1997; 3: 1034-6.
24. 2 arrest after DNA damage. Science 1998; 282: 1497-501.
25. Rigberg D A, Blinman T A, Kim F S, Cole M A, McFadden D W. Antisense blockade of p21/waf1 decreases radiation-induced G2 arrest in esophageal squamous cell carcinoma. J Surg Res 1999; 81: 6-10.
26. Xiong Y, Hannon G J, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
27. Okuyama T, Maehara Y, Kabashima A, Takahashi I, Kakeji Y, Sugimachi K. Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology 2002; 63: 353-61.
28. WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 1999; 5: 2445-9.
29. WAF1/CIP1, and bcl-2 in resistant colorectal carcinoma. Hum Pathol 1997; 28: 1189-95.
30. Shinozaki H, Ozawa S, Ando N et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res 1996; 2: 1155-61.